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Abstract: Increasing evidences show that the ATPase Inhibitory Factor 1 (IF1), the physiological
inhibitor of the ATP synthase, is overexpressed in a large number of carcinomas contributing to
metabolic reprogramming and cancer progression. Herein, we show that in contrast to the findings in
other carcinomas, the overexpression of IF1 in a cohort of colorectal carcinomas (CRC) predicts less
chances of disease recurrence, IF1 being an independent predictor of survival. Bioinformatic and
gene expression analyses of the transcriptome of colon cancer cells with differential expression of IF1
indicate that cells overexpressing IF1 display a less aggressive behavior than IF1 silenced (shIF1) cells.
Proteomic and functional in vitro migration and invasion assays confirmed the higher tumorigenic
potential of shIF1 cells. Moreover, shIF1 cells have increased in vivo metastatic potential. The higher
metastatic potential of shIF1 cells relies on increased cFLIP-mediated resistance to undergo anoikis
after cell detachment. Furthermore, tumor spheroids of shIF1 cells have an increased ability to escape
from immune surveillance by NK cells. Altogether, the results reveal that the overexpression of IF1
acts as a tumor suppressor in CRC with an important anti-metastatic role, thus supporting IF1 as a
potential therapeutic target in CRC.
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1. Introduction
Colorectal cancer is the third most common type of cancer worldwide [1] and the need for
biomarkers that inform of disease progression is required. A large number of studies have highlighted
the importance of metabolism in cancer initiation and progression [2,3]. Mitochondria play a central
role in intermediary metabolism, the provision of metabolic energy and in cellular signaling [4,5].
A primary hub of mitochondrial activities is the ATP synthase, the engine of oxidative phosphorylation
that utilizes the proton electrochemical gradient generated by the respiratory chain for the synthesis of
ATP [4]. Inhibition of the ATP synthase results in the inhibition of mitochondrial respiration and the
concurrent activation of aerobic glycolysis, which is a hallmark of proliferation in normal, cancer and
stem cells [4,6–8]. An enhanced glycolytic flux provides the carbon skeletons and reductive power
required for the biosynthesis of amino acids, lipids, nucleotides and energy that are necessary to sustain
proliferation [9,10].
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The ATPase Inhibitor Factor 1 (IF1) is a physiological inhibitor [11–13] and structural organizer [14]
of the mitochondrial ATP synthase in tissues where it is normally expressed [15], as recently stressed
in vivo [16–18]. IF1 is expressed at low levels in normal human colon, lung and breast tissues [15]
but is highly overexpressed in the carcinomas arising in these tissues [13]. Moreover, the activity
of IF1 as inhibitor of the ATP synthase is regulated by phosphorylation [19]. Dephosphorylated IF1
binds and inhibits the activity of the enzyme in hypoxia and during progression through the cell
cycle whereas phosphorylated IF1 is unable to bind the enzyme and allows ATP synthesis upon
an increase in energy demand in cardiac muscle in vivo [19]. In colon, lung and breast carcinomas,
IF1 is largely present in its dephosphorylated state and hence active as an inhibitor of the ATP
synthase [19]. Consistently, a high expression level of IF1 in human hepatocarcinomas [20], bladder [21]
and stomach [22] carcinomas and in gliomas [23] is associated with a worse overall and/or disease
free survival of the patients. In agreement with the pro-oncogenic role of IF1, we have observed that
diethylnitrosamine-induced hepatocarcinogenesis in mice that overexpress an active IF1 mutant in the
liver develop more and bigger tumors than control mice [16]. Mechanistically, the overexpression of IF1
in human hepatocarcinomas [20] activates the NFκB pathway and primes metastatic disease through
Snai1- and VEGF-guided epithelial to mesenchymal transition (EMT) and angiogenesis, respectively.
Although the pro-oncogenic role of IF1 is supported in a large set of human cancers, its high
expression level in the carcinomas is not always associated with a poorer patient outcome. In fact,
disease free survival of breast cancer patients is significantly extended when the carcinomas overexpress
IF1 [13,24]. Moreover, evidence from the ongoing study of a cohort of colon cancer patients indicated
that a high expression of IF1 in the carcinomas also predicts a better overall survival for the patients [13].
Altogether, the purpose of this study was to deepen into the significance of IF1 as a biomarker of
colorectal carcinomas (CRC) prognosis and to investigate the mechanisms underlying the role of IF1
in colon cancer progression. The findings in the cohort of CRC patients studied indicate that the
tumor content of IF1 is an independent predictor of survival, advancing that a high tumor content
of IF1 predicts longer time-periods for disease recurrence. Mechanistically, the results support that
the overexpression of IF1 in colon cancer cells prevents metastatic disease by favoring anoikis and
immune surveillance of the tumors by NK cells of the innate immune system.
2. Results
2.1. Increased Expression of IF1 Is Associated with Increased Survival of CRC Patients
Figure 1A shows representative images of the immunostaining of IF1 in normal and tumor
tissue of colon cancer patients to illustrate the increase in IF1 expression triggered by carcinogenesis.
Recombinant human IF1 (r-IF1) [12] was used to estimate the approximate amount of IF1 present in
normal and tumor tissue of cancer patients (Figure 1B and Figure S3). The plot of the linear increased
in signal when the amount of r-IF1 increases (Figure 1B and Figure S3) was used to interpolate the
values of native IF1 signals in the samples (Figure 1B and Figure S3). The results indicate that the
tumor content of IF1 roughly increased by a factor of two when compared to the adjacent normal tissue
(Figure 1B and Figure S3). A similar two-fold increase in the tumor content of IF1 was observed in a
larger cohort of 37 normal and paired CRC biopsies using “reverse phase protein arrays” (Table S1).
Kaplan–Meier survival analysis revealed a highly significant association between the tumor content of
IF1 and disease free survival (DFS) of the patients (Figure 1C). A low content of IF1 in the carcinomas
correlated with higher chances of developing metastatic disease (Figure 1C, Table 1).
Univariate Cox regression analysis of seven variables (Table 1) as potential predictors of OS and
DFS in colon cancer patients showed significant association of lymph nodes, metastasis, CEA and IF1
expression with OS and DFS of the patients (Table 1). Age also associated with DFS of the patients
(Table 1). In multivariate Cox model the results showed that the best predictive factor for OS and DFS
was the tumor content of IF1 (Table 1), stressing the relevant role of IF1 as an independent predictor of
survival in CRC patients.
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Figure 1. Expression of IF1 in human colon carcinomas. (A) Representative staining of IF1 expression 
in normal and tumor tissue of the colon. Magnification 25x. (B) Western blots show IF1 and β-F1-
ATPase (β-F1) in paired normal (N) and tumor (T) biopsies derived from three representative patients 
and increasing amounts of the recombinant IF1 (r-IF1) protein (0–200 ng). Linear correlations between 
the fluorescence intensity (arbitrary units) of the spots and the amount of recombinant protein. The 
histogram shows significant differences in the expression of IF1 between the two groups of samples. 
Protein concentration was calculated according to the fluorescence intensity obtained in r-IF1 plot. 
The results shown are mean ± S.E.M; *, p < 0.05 when compared to its respective control. (C) Kaplan–
Meier curves for disease-free survival probability for the cohort of 37 colon cancer patients stratified 
by the tumor expression level of IF1. The log-rank test p-value (p < 0.0004) is shown. 
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DFS in colon cancer patients showed significant association of lymph nodes, metastasis, CEA and IF1 
expression with OS and DFS of the patients (Table 1). Age also associated with DFS of the patients 
(Table 1). In multivariate Cox model the results showed that the best predictive factor for OS and DFS 
was the tumor content of IF1 (Table 1), stressing the relevant role of IF1 as an independent predictor 
of survival in CRC patients. 
Table 1. Univariate and multivariate Cox regression analysis for overall survival and disease-free 
survival in colorectal cancer patients. 
Univariate Analysis Overall Survival Disease-Free Survival 
Variable HR (95% CI) p-value HR (95% CI) p-value 
Age (year) 
≤70 
1 (Reference)  1 (Reference)  
>70 3.01 (0.97 9.27) 0.055 3.67 (1.20 11.23) 0.022 
Gender 
Female 
1 (Reference)  1 (Reference)  
Male 0.59 (0.22 1.53) 0.280 0.58 (0.22 1.47) 0.252 
Grade 
I 
1 (Reference)  1 (Reference)  
II 2.94 (0.38 22.62) 0.300 3.56 (0.46 27.27) 0.221 
III 7.094 (0.78 63.99) 0.081 8.62 (0.95 78.21) 0.055 
Figure 1. Expression of IF1 in human colon carcinomas. (A) Representative staining of IF1 expression in
normal and tumor tissue of the colon. Magnification 25x. (B) Western blots show IF1 and β-F1-ATPase
(β-F1) in paired normal (N) and tumor (T) biopsies derived from three representative patients and
increasing amounts of the recombinant IF1 (r-IF1) protein (0–200 ng). Linear correlations between
the fluorescence inten ity (arbitrary units) of the p ts and the amount of recombinant protein.
The histogram shows significant differences in he xpres ion of IF1 between the two groups of
samples. Protein concentration was calculated according to the fluorescence intensity obtained in
r-IF1 plot. The results shown are mean ± S.E.M; *, p < 0.05 when compared to its respective control.
(C) Kaplan–Meier curves for disease-free survival probability for the cohort of 37 colon cancer patients
stratified by the tumor expression level of IF1. The log-rank test p-value (p < 0.0004) is shown.
Table 1. Univariate and multivariate Cox regression analysis for overall survival and disease-free
survival in colorectal cancer patients.
Univariate Analysis Overall Survival Disease-Free Survival
Variable HR (95% CI) p-Value HR (95% CI) p-Value
Age (year)
≤70 1 (Reference) 1 (Reference)
>70 3.01 (0.97–9.27) 0.055 3.67 (1.20–11.23) 0.022
Gender
Female 1 (Reference) 1 (Reference)
Male 0.59 (0.22–1.53) 0.280 0.58 (0.22–1.47) 0.252
Grade
I 1 (Reference) 1 (Reference)
II 2.94 (0.38–22.62) 0.300 3.56 (0.46–27.27) 0.221
III 7.094 (0.78–6 .99) 081 8.62 (0.95–78.21) 0.055
Lymph nodes
No 1 (Reference) 1 (Reference)
Yes 4.62 (1.49–14.30) 008 3. 1 (1.28–10.23) 0.015
CEA
≤5 µg/L 1 (Reference) 1 (Reference)
>5 µg/L 2.79 (1.06–7.36) 0.038 2.64 (1.02–6.86) 0.045
Metastasis
No 1 (Reference) 1 (Reference)
Yes 4.34 (1.57–11.94) 0.004 3.87 (1.42–10.52) 0.008
IF1
Low 1 (Reference) 1 (Reference)
High 0.176 (0.06–0.49) 0.001 0.19 (0.07–0.52) 0.001
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Table 1. Cont.
Multivariate Analysis Overall Survival Disease-Free Survival
Variable HR (95% CI) p-value HR (95% CI) p-value
Age (year)
≤70 -- - - - - - - - - - - - - 1 (Reference)
>70 -- - - - - - - - - - - - - 2.50 (0.76–8.21) 0.131
Lymph nodes
No 1 (Reference) 1 (Reference)
Yes 3.18 (0.95–10.61) 0.059 2.25 (0.71–7.13) 0.165
CEA
≤5 µg/L 1 (Reference) 1 (Reference)
>5 µg/L 0.96 (0.17–5.20) 0.960 1.31 (0.21–7.98) 0.767
Metastasis
No 1 (Reference) 1 (Reference)
Yes 3.23 (0.55–18.77) 0.191 1.94 (0.31–12.08) 0.476
IF1
Low 1 (Reference) 1 (Reference)
High 0.250 (0.08–0.76) 0.015 0.32 (0.10–0.99) 0.049
2.2. Transcriptomic Profiling of HCT116 Cells with Differential Expression of IF1
To investigate the molecular basis of the apparent anti-oncogenic role of IF1 in colon cancer we
developed stable HCT116 cell lines overexpressing (IF1) or silencing (shIF1) IF1. The expression of IF1
in the resulting cells was assessed by immunoblotting (Figures S1A and S3) and immunofluorescence
microscopy (Figures S1B and S3) compared to their respective controls. Roughly, a four-fold difference
in IF1 expression could be noted between shIF1 and IF1 overexpressing cells.
Analysis of the transcriptome of control (empty vector, EV), shIF1 and IF1 cells revealed that
the comparison between silenced and overexpressing cells displayed greater number of differentially
expressed genes (Figure 2A and Tables S4–S6). For this reason, subsequent analysis of the transcriptome
was performed with the shIF1 vs. IF1 comparison. Bioinformatic analysis showed that from the list
of significant genes, 143 were upregulated and 126 were downregulated in shIF1 cells (Figure 2A).
A volcano plot that combines the statistical significance with the magnitude of change illustrates the
distribution of the IF1-regulated genes emphasizing those that display large magnitude of significant
change (Figure 2B). Consistently, the ATPIF1 gene was found significantly downregulated in shIF1
cells (Figure 2B). For enrichment analysis, we used the Genecodis tool categorizing the genes into
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The most affected pathways in shIF1
cells were related to metabolism, pathways in cancer and the cell cycle (Figure 2C).
The set of differentially expressed genes was interrogated with the ingenuity pathways analysis
(IPA). This tool is able to predict the activation/repression status of the affected pathways. Unsupervised
hierarchical clustering analysis of the 89 genes obtained in IPA confirmed the existence of large
differences between shIF1 and IF1 cells (Figure 2D). Differences in the expression of several of these
genes were validated by real time PCR confirming the microarray results (Figure 2E). The IPA analysis
showed that the majority of activated pathways in shIF1 cells are known to increase the aggressiveness
of cancer (Figure 2F). In contrast, the repressed pathways in shIF1 cells were related with cell cycle
regulation (Figure 2F), in agreement with the enrichment analysis. Moreover, the analysis of diseases
and functions highlighted that the activated pathways in shIF1 cells are related with more aggressive
behavior (Figure 2G). Altogether, the results suggest that the overexpression of IF1 in colon cancer cells
induces a less invasive phenotype.
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Figure 2. Transcriptome of colon cancer IF1-overexpressing and IF1-silenced cells. (A) Representation 
of the total number of significantly affected genes in the comparisons between four different 
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Figure 2. Transcriptome of colon cancer IF1-overexpressing and IF1-silenced cells. (A) Representation of
the total number of significantly affected genes in the comparisons between four different preparations
(1–4) of control, silenced and overexpressing IF1 cells using Agilent 8 × 60K Human arrays. (B) Volcano
plot with some relevant genes indicated. X axis represents the expression fold change of the affected genes
and the Y axis represents –log10 of the false discovery rate (FDR) values. (C) Gene enrichment analysis,
showing the information related to KEGG. (D) Hierarchical clustering analysis using differentially
expressed genes implicated in IPA pathways. Four different samples of each cell type were included in
the arrays. (E) Quantitative reverse transcription PCR validation of up- and down-regulated genes
in the microarray analysis in shIF1 (red bars) and IF1 (green bars) cells. *, p ≤ 0.05 by Student’s t test.
(F,G) Pathways (F) and diseases and functions (G) affected by silenced IF1 cells as reveal by the IPA
ingenuity tool. Z-score indicates the overall predicted activation/inhibition state of the function.
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2.3. Proteomic Analysis of HCT116 Cells with Differential Expression of IF1
Isobaric tags for relative and absolute quantitation (iTRAQ) experiments were performed to
identify the major proteomic changes between shIF1 and IF1 cells. A list of 4853 peptides corresponding
to 25 protein groups were differentially expressed between shIF1 and IF1 cells as shown in the volcano
plot (fold change ≥ 1.5; Figure 3A, see also Table S7). Hierarchical clustering of the differentially
expressed proteins revealed several proteins that were differentially expressed (Figure 3B). The analysis
with the Genecodis tool and Panther database showed that proteins upregulated in shIF1 cells are
implicated in the regulation of the actin cytoskeleton, cell cycle and migration, anti-apoptosis, tight
junction and focal adhesion pathways (Figure 3C). Consistently, the proteins downregulated in shIF1
cells are related to the apoptotic and proteasome degradation pathways (Figure 3C). IPA analysis of
the differentially expressed proteins also predicted the activation of cellular movement in shIF1 cells
when compared to cells overexpressing IF1 (Figure 3D). Taken together, the results also support at
the proteomic level that silencing IF1 is related with an increase in the migration potential of colon
cancer cells.
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Figure 3. iTRAQ analysis of two different (1–2) preparations of IF1 and shIF1 cells. (A) Volcano plot of
the proteins quantified in iTRAQ analysis. The plot shows the ratio (shIF1/IF1) and significance on
the X and Y axes, respectively. (B) Hierarchical clustering analysis based on significant differences in
protein expression level between IF1-silenced and overexpressing cells. (C) Pathways affected in shIF1
cells analyzed by Genecodis and Panther. (D) Activated pathway in shIF1 cells analyzed by IPA.
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2.4. Phenotypic Analysis of HCT116 Cells with Differential Expression of IF1
Overall, the transcriptomic and proteomic data suggested that colon cancer cells with a low
expression of IF1 have a higher tumorigenic potential. Indeed, the rates of cellular proliferation
showed that shIF1 cells proliferate faster than IF1 cells (Figure 4A,B). In agreement with previous
results on the role of IF1 in controlling mitochondrial respiration [11–13], cells overexpressing IF1
showed partial inhibition of mitochondrial respiration (Figure 4C). Wound healing assays revealed
that shIF1 cells started filling and fully occupied the scratched area earlier than IF1 cells (Figure 4D).
Besides, soft-agar colony-formation assays showed that shIF1 cells had more capacity to grow and
form colonies in the anchorage-independent assay (Figure 4E). Moreover, cell death assays triggered
by treatment of the cells with staurosporine or hydrogen peroxide further revealed that shIF1 cells are
more resistant to apoptosis inducing agents than IF1 cells (Figure 4F). Overall, these results support
that colon cancer cells with a low content of IF1 have greater potential for tumor growth and metastasis
than IF1 overexpressing cells.
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Figure 4. IF1-silenced colon cancer cells have more aggressive phenotype. Cellular proliferation
in shIF1 (red lines and bars) and IF1 (green lines and bars) was assessed by protein concentration
(n = 3; A) and by the incorporation of EdU (n = 6; B) into cellular DNA. (C) Rates of basal, oligomycin
sensitive and maximum respiration in shIF1 and IF1 cells determined in the X24 Seahorse Flux Analyzer
(n = 3). OL, olig mycin; DNP, dinitrophenol; R + A, rotenone + antimycin A. (D) Time frames of the
wound-healing assay and its qu ntification (n = 3). Magnification 4x. (E) Anchorage-independent
growth in soft-agar and its quantification (n = 4). Magnification 10x. (F) Cell death determination by
flow cytometry using Annexin V staining after overnight treatment with 0.25 µM staurosporine (STS)
and 60 µM hydrogen peroxide (H2O2) (n = 5). (A–F) Results shown are means ± S.E.M; *, p ≤ 0.05 by
Student’s t test.
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2.5. In Vivo Tumorigenesis of HCT116 Cells with Differential Expression of IF1
To assess the tumor growth capacity of the cells in vivo, shIF1 and IF1 cells were subcutaneously
injected into the left and right flank of nude mice, respectively (Figure 5A). After implantation,
tumor growth and volume were monitored after the administration of luciferin using IVIS Lumina II
(Figure 5B,C). The results showed that the differential expression of IF1 had no relevant effect on the
in vivo rates of tumor growth of the cells. In contrast, intravenous injection of shIF1 and IF1 cells into
nude mice to assess metastatic disease in vivo revealed that shIF1 cells increased the percentage of
mice with lung metastases, being the number and growth of metastases bigger (Figure 5D). Altogether,
supporting that a low expression of IF1 in colon cancer cells favors metastatic disease.Cancers 2019, 11, x FOR PEER REVIEW 9 of 20 
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2.6. IF1 Favors Anoikis of Colon Cancer Cells
Detachment of epithelial cells from the extracellular matrix results in a form of programmed cell
death known as anoikis [25]. Importantly, anoikis resistance is a critical mechanism supporting tumor
metastasis [25]. Interestingly, shIF1 cells showed more resistance to anoikis than IF1 cells upon cell
detachment (Figure 6A). In an attempt to unveil the potential mechanisms that might underpin the
anoikis resistance of shIF1 cells we searched for the differential expression of Snai1, a transcription
factor involved in EMT, hepatocyte growth factor (HGF) and the activation of PI3K/Akt, mTOR,
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p38 and ERK1/2 MAPK, NFκB and AMPK signaling pathways, which are positive regulators of anoikis
resistance (Figures S2, S4 and S5). However, we found no relevant differences in the expression and/or
activation of these signaling pathways between shIF1 and IF1 cells (Figure S2,S4 and S5). In contrast,
cFLIP (FLICE-inhibitory protein), which is a potent inhibitor of receptor-mediated cell death upon
cellular detachment from the extracellular matrix [26,27], was significantly overexpressed in shIF1 cells
when compared to overexpressing IF1 cells (Figure 6B and Figure S3). Consistently, the tissue content
of cFLIP in normal colon was significantly increased when compared to that present in the tumors
(Figure 6C and Figure S3), inversely correlating with the expression of IF1 (Figure 1B and Figure S3).
Overall, the results support that cFLIP mediated anoikis resistance favors the pro-metastatic phenotype
of shIF1 cells.Cancers 2019, 11, x FOR PEER REVIEW 10 of 20 
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2.7. IF1 Favors Infiltration and Cytotoxicity of ells
Mitochondria are cellular t i l i t iff re t olecules that
emanate from their activity [5,28]. I t i r t t tra sgenic ice that
overexpres IF1 in colon mitochondria promote the recruitment of anti-inflam atory im une cells in
response to inflammation when compared to wild-type mice [29]. Henc , we next investigated he role
of natural killer (NK) cells in tumor infiltration and cytotoxicity of umor spheroids develop d from
IF1 or shIF1 cells. To this end, colo ospheres (Figure 7A) were co-cultured wi h primary IL-2 and I -15
pre-activated and expande CD45-APC stained NK cells at 1:5 ratio and the tumor spher id int gr ty,
NK infiltration and cytotoxicit was monitored by light and fluorescenc microscopy 48 h latter
(Figure 7). Th infiltration of NK cells in tumor spheroids d veloped from IF1 overexpressing cell was
significantly increased when compared to shIF1 spheroids, as assessed both by immunofluorescence
microscopy (Figure 7A) and by flow cytometry (Figure 7B). Eventually, the formation of lytic NK-cell
immunological synapses [30] with cancer cells of the spheroids were observed (Figure 7C). Assessment
of granzyme B-induced cell death by the quantification of cells showing the activation of the tumor
suppressor phospho-p53, indicated a significant increase of dying cells in the IF1 spheroids (Figure 7D).
Overall, the results support that a low expression level of IF1 in colon cancer cells favors metastatic
disease because the operation of at least two contributing factors: (i) the higher resistance of cancer
cells to undergo anoikis upon cell detachment and, (ii) the lower tumor infiltration and cytotoxicity of
NK cells observed in these carcinomas. Altogether, the results provide a molecular and functional
explanation for the higher incidence of CRC recurrence in patients bearing carcinomas with low
expression of IF1 (Figure 1C, Table 1).
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Figure 7. IF1-silenced colon cancer spheroids were more resistant to NK cells invasion and cytotoxicity.
(A) Bright field microscopy of IF1-overexpressing and IF1-silenced spheroids without NK cells (upper
panels) and confocal microscopy images (middle panels) from IF1-overexpressing and IF1-silenced
spheroids co-cultured for 48 h with CD45-APC stained NK cells. Lower panels are a zoom of the
indicated area in middle panels. Nuclei: blue, DAPI staining; CD45+ cells: red. Histograms
show the quantification of CD45+ cells/mm2 by immunofluorescence microscopy (n = 5) (A) and
CD45+ cells/spheroid by flow cytometry (B). For flow cytometry, results shown are means of eight
IF1-overexpressing or IF1-silenced spheroids ± S.E.M. (C) Confocal microscopy images of lytic
NK-immunological synapses. Nuclei: blue; CD45+ cells: red; Granzyme B: green. (D) Colon cancer
cytotoxicity by NK cells was assessed by quantification of phospho-p53 staining (green) by confocal
microscopy. Two representative preparations (Sph1 and Sph2) are shown for IF1-overexpressing and
IF1-silenced spheroids co-cultured with NK cells for 48 h. Histogram shows the quantification of p-p53+
cells/mm2 (n = 4). *, p ≤ 0.05 by Student’s t test. IF1, IF1-overexpressing cells are represented by green
bars and shIF1, IF1-silenced cells by red bar. (E) Hypothetical scheme based on transcriptomic data
(Table S6) showing the increased expression of the CXC chemokine receptor 4 (CXCR4, three fold, FDR
< 0.005), transcription factor SMAD3 (two fold, FDR < 0.04), ecto- 5’nucleotidase CD73/NT5E (three
fold, FDR < 0.005) and LDHA (two fold, FDR < 0.007) in shIF1 cells that might contribute to lessening
immune surveillance. Adenosine and lactate in the microenvironment contribute to immunometabolic
suppression (red) whereas CXCR4 signaling inhibits activation and proliferation of NK cells (blue).
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3. Discussion
The mitochondrial ATP synthase is a critical component regulating energy metabolism, cellular
signaling and death, playing the activity and expression of its physiological inhibitor a prominent
role [31]. The ATPase Inhibitory Factor 1 is upregulated in different carcinomas [4,12,20,22] triggering
metabolic reprograming of the cell by inhibition of mitochondrial respiration and concurrently
activating programs aimed at proliferation and survival [4,11]. IF1 is a mitochondrial protein with a
very short half-life (2 h) in colon cancer [13] and in stem [6] cells when compared to the half-life of
other subunits of the ATP synthase (18 h) [32]. Since the high expression of IF1 observed in CRC is
unrelated to changes in the cellular availability of IF1 mRNA [13], we suggest that its accumulation in
carcinomas should result from oncogenic transformation of the mechanisms that regulate IF1 mRNA
translation and/or the stability of the protein. Evidence for the operation of both mechanisms of
posttranscriptional regulation of IF1 expression has already been provided [6,15], thus emphasizing
their potential contribution in the pathophysiology linked to IF1 expression.
Not surprisingly, the overexpression of IF1 in hepatocarcinomas [20], bladder [21] and stomach [22]
carcinomas and in gliomas [23] contributes, by different mechanisms, to cancer recurrence and
progression. Contrariwise, we show that its overexpression in a cohort of carcinomas of the Spanish
CRC Epicolon Study [33] identifies patients with less chances of disease recurrence, supporting an
anti-metastatic role for IF1. Moreover, we show that IF1 is a significant independent predictor of
good prognosis in colon cancer patients. Similarly, the overexpression of IF1 in breast carcinomas also
predicts lower chances of disease recurrence [13,24].
To investigate the mechanisms that support the paradoxical anti-oncogenic role of IF1 in colon
cancer progression we have developed HCT116-luc colon cancer cells stably expressing low or high IF1
levels. Through a comprehensive transcriptomic, proteomic and in vitro tumorigenic assays we show
that colon cancer cells with low IF1 expression have a more pro-oncogenic phenotype with increased
migratory and invasive capabilities and increased capacity to evade death than IF1 overexpressing
cells. For instance, shIF1 cells revealed deregulated cell cycle, which is a hallmark of cancer cells [34],
and predicted the inhibition of the PPAR signaling pathway that is known to inhibit the proliferation of
tumor cells [35]. In the same line, a low expression of PPA receptor γ is associated with reduced patients’
survival [36]. On the other hand, p21-activated kinase (PAK), Ephrin receptor, p38 MAPK, ERK/MAPK,
HGF, PDGF and renal cell carcinoma signaling, that are known to increase the aggressiveness of cancer,
are predicted pathways activated in shIF1 cells at the transcriptomic level, although no evidence for
such activations were obtained at the protein level.
Remarkably, although cancer cells reprogram metabolism to divert metabolites into the anabolic
pathways that support proliferation [6–8,37–39], it has been shown that migratory/invasive cancer cells
specifically favor mitochondrial respiration and increased ATP production [40,41]. In agreement with
this observation, we show that shIF1 cells have a higher respiratory activity of mitochondria than
cells overexpressing IF1, also in agreement with similar findings reported in breast cancer cells with
low expression of IF1 [24], further stressing the relevant role of mitochondrial bioenergetic function
in metastatic disease. Interestingly, although the growth rates of the cells in vitro were statistically
different, they had marginal relevance as assessed in vivo, suggesting that the metabolic differences
between shIF1 and IF1 cells are unnoticeable for the accretion of tumor mass.
The majority of mortalities caused by colorectal cancer derive from metastatic disease to the liver
or lung [42]. When the metastatic potential of the cells was investigated by its ability to colonize the
lung, we observed that a low expression of IF1 conferred an increased metastatic potential to shIF1 cells
in vivo. Interestingly, shIF1 cells overexpressed cFLIP, a master cell-death regulator that suppresses
tumor necrosis factor-α (TNF-α), Fas-L and TNF-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis, to prevent the activation of the caspase 8 cascade in the death-inducing signaling complex
(DISC) [26,27]. Thus, we suggest that a likely factor that contributes to the increased metastatic potential
of shIF1 cells is their increased capacity to evade anoikis.
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NK cells represent a first line of defense of the innate immune system because this special
type of lymphocytes lyses tumor cells without prior sensitization, thus playing a prominent role in
immune surveillance to prevent metastatic disease [43,44]. We show that an additional factor that
contributes to the increased metastatic potential of shIF1 cells is the diminished NK cell infiltration
and resulting cell-death in shIF1-colonospheres. Importantly, tumor infiltration of NK cells coincides
with cytotoxicity and is associated with a better prognosis in colorectal cancer [45]. Cytotoxicity of
activated NK cells is exerted by multiple approaches, including the direct lysis of the cancer cell by
cytolytic proteins such as perforin and granzymes [46], as we have observed in polarized granules in
lytic NK-cell immunological synapses. In addition, shIF1 cells could diminish immune surveillance
of NK cells by generating soluble activating receptor ligands, such as cFLIP to block induction of
apoptosis by TNF-α, Fas-L/Fas and TRAIL receptors [47]. Interestingly, shIF1 cells reveal significant
increased expression of the CXC chemokine receptor 4 (CXCR4), which is involved in the inhibition of
the activation and proliferation of NK cells by tumor cells [48,49] (Figure 7E). Moreover, shIF1 cells
significantly increased the expression of the transcription factor SMAD3 and of the ecto-5’nucleotidase
CD73/NT5E, which is under the control of SMAD3, an enzyme that generates adenosine in the tumor
microenvironment leading to the suppression of multiple immune subsets including NK cells [50,51]
(Figure 7E). In addition, the mRNA of LDHA (two fold, false discovery rate (FDR) < 0.007) was
also significantly increased in shIF1 cells, suggesting that they produce more lactate which might be
released to the tumor microenvironment acting also as an immune metabolite that hampers immune
surveillance and activation of NK cells [52] (Figure 7E). Altogether, metabolic immune suppression by
the tumor microenvironment and enhanced CXCR4 signaling could be involved in lessening immune
surveillance of shIF1 carcinomas (Figure 7E).
We should stress the dissimilar behavior reported for IF1 as biomarker in cancer prognosis [31].
In this regard, we suggest that the large differences observed in the tissue-specific expression of IF1
might underlie this behavior [15]. For instance, in the case of liver and stomach, IF1 expression
is highly abundant in the normal tissue [13,15] and its overexpression in oncogenesis predicts bad
patient prognosis [20,22]. In contrast, the overexpression of IF1 in colon (this study) and breast
carcinomas [13,24] is a biomarker of good prognosis. However, at variance with liver and stomach,
colon and breast are tissues with low expression of IF1 under normal physiological conditions (this
study and [13,24]), suggesting that IF1, in addition to its structural [14] and inhibitory functions on the
ATP synthase [19], has additional tissue-specific functional roles [15,31].
Altogether, the results indicate that an elevated expression of IF1 in CRC predicts a favorable
prognosis for colon cancer patients. Indeed, the overexpression of IF1 in CRC represents a great
advantage over carcinomas with low expression of IF1 because in the latter case metastatic disease is
favored by the ability of the cells to escape anoikis and immune surveillance by NK cells.
4. Materials and Methods
4.1. Patient Specimens and IF1 Quantification
A collection of frozen tissue sections obtained from surgical specimens of untreated cancer patients
with primary colorectal adenocarcinomas, enrolled in the incident Spanish CRC Epicolon Study and
prospectively followed during 5 years were included in this study [33]. Patients’ medical records were
reviewed and identifiers coded to protect patient confidentiality. Normal and tumor samples, supplied
by the Banco de Tejidos y Tumores, Department of Pathology, Hospital Meixoeiro, Vigo, Spain, were
provided with the understanding and written consent from the patients. The study methodologies
conformed to the standards set by the Declaration of Helsinki and were approved by the Institutional
Review Board “CEIC de Galicia: 2010/039”. The clinicopathological characteristics and IF1 content in
paired normal and tumor biopsies of the CRC patients studied are provided in Table S1. The content of
IF1 in normal (2.2 ± 0.1 pg/ng protein) and tumor (3.6 ± 0.4 pg/ng protein) biopsies of this cohort of
CRC were determined by reverse phase protein arrays using recombinant hIF1 [13].
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4.2. Generation of Cell Lines, Cell Cultures and Spheroids
The human HCT116 and HCT116-luc (Caliper Life Sciences, Inc., Hopkinton, MA, USA) colon
cancer cells were cultured in McCoy’s 5A media. For the IF1 overexpression approach, the pCDH-CMV-
MCS-EF1-RFP + PURO cDNA Cloning and Expression Vector (SBI#CD616B-2; SBI System Biosciences,
Palo Alto, CA, USA) was used to establish cells overexpressing the human ATPase IF1 [24]. For the
IF1 silencing approach, we used the pEco-Lenti-U6 shRNA-(RFP-puro) (GenTarget Inc, San Diego,
CA, USA. # LTSH-U6-RP) silencer plasmid encoding the IF1 shRNA3 (Invitrogen, Thermo Fisher
Scientific, Waltham, MA, USA) driven by the U6 promoter [24]. Stable cell lines were generated using
lentivirus [24]. Viral particles were produced in HEK293T cells. After transfection, stable transfectants
were selected by adding 6 µg/mL puromycin (Invitrogen) to the growth medium.
For spheroid formation, 3 × 103 IF1 or shIF1 HCT116 cells were seeded for each spheroid.
After three days, the spheroids were transferred to non-adherent Nunclon Sphera™ 96F-well plate
(ThermoFisher Scientific). The addition of CD45-APC stained NK cells was done one day after.
4.3. NK Cell Isolation and Labeling
Primary NK cells were isolated from buffy coats of healthy donors provided by Centro de
Transfusión de la Comunidad de Madrid (Spain) obtained according to the Principles of the Declaration
of Helsinki. Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation on
Lymphoprep (Stemcell Technologies, Vancouver, BC, Canada) and Percoll (GE Healthcare, Chicago,
IL, USA). PBMCs from the 1.068 density layer were cultured for 1 week in RPMI 1640 (Lonza, Basel,
Switzerland) with 10% FBS (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 5% human AB
serum (Sigma-Aldrich, St. Louis, MO, USA), 10 mM HEPES, penicillin/streptomycin (10 U/mL) and
2 mM L-glutamine (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 50 IU/mL of recombinant
human rhIL-2 (Peprotech, Rocky Hill, NJ, USA) and 20 IU/mL of rhIL-15 (NISBC, Blanche Lane, UK).
For NK cell purification, cultures were depleted of T, B and myeloid cells by magnetic sorting using
CD4-PE (Beckman Coulter, Brea, CA, USA), CD3-PE, CD19-PE, CD13-PE mAbs (BD Biosciences, San
Jose, CA, USA) and anti-PE microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany). Negative
cells containing NK cells (>80% purity) were isolated by LS columns (Miltenyi Biotech, Bergisch
Gladbach, Germany). For spheroid co-cultures, NK cells were labeled with APC-coupled anti-human
CD45 or mouse IgG1 control antibodies (BD Biosciences).
4.4. Cellular Lysis and Western Blotting
Cell lysis was performed with RLN-T buffer (RLN buffer plus 0.5% Triton X-100 and the complete
protease inhibitors cocktail EDTA-free; Roche, Basel, Switzerland) at 20 × 106 cells/mL for 5 min on ice
and cellular extracts prepared [53]. See Table S2 for antibodies used in western blotting.
4.5. Gene Array Hybridization
Total RNA was extracted using Trizol (Invitrogen) followed by the Qiagen RNeasy (Qiagen,
Hilden, Germany). Total RNA (200 ng) was amplified using the One Color Low Input Quick Amp
Labeling Kit (Agilent Technologies) and purified with the RNeasy Mini Kit (Qiagen). Preparation of
probes and hybridization was performed as described in One-Color Microarray Based Gene Expression
Analysis Manual Ver. 6.5, Agilent Technologies as recently described in detail [24]. Slides were Sure
Print G3 Agilent 8 × 60K Human (G4852A-028004). Images were captured with an Agilent Microarray
Scanner and spots quantified using Feature Extraction Software (Agilent Technologies, Santa Clara,
CA, USA). Hybridizations and statistical analysis were performed by the Genomics Facility at Centro
Nacional de Biotecnologia (Madrid, Spain).
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4.6. Gene Data Analysis
Genes with a fold change ≥2 or ≤−2 between control, overexpressing and silenced IF1 cells were
selected. A corrected p-value ≤ 0.01 was considered statistically significant. Genecodis3 tool was used
to perform gene set enrichment analysis using KEGG and Panther pathways enrichments. Gene set
enrichment by Ingenuity Pathway Analysis (Qiagen) was also used to determine the specific canonical
signaling pathways and related diseases and functions affected. A Fisher’s exact right-tailed test
identified significantly enriched pathways, and a z score was provided.
4.7. Quantification of mRNA
Reverse transcription reactions were performed using 1 µg of total RNA and the High Capacity
Reverse Transcription Kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). Real-time polymerase
chain reaction (PCR) was performed with an ABI PRISM 7900HT SDS (Applied Biosystem, Waltham,
MA, USA) and Power SYBR Green PCR Master Mix (Applied Biosystems). See Table S3 for primers used.
4.8. Proteomic Analysis and ITRAQ Labeling
Disulfide bonds from cysteinyl residues in proteins were reduced with 10 mM DTT and the thiol
groups alkylated with 50 mM iodoacetamide. Proteins were digested in situ with sequencing grade
trypsin (Promega). Digestion was stopped by the addition of 1% TFA. Whole supernatants were dried
down and then desalted onto OMIX Pipette tips C18 (Agilent Technologies, Santa Clara, CA, USA).
The peptides from tryptic digests (100 µg) were labeled using chemicals from the iTRAQ reagent 8plex
Multi-plex kit (reagents 113, 114, 115, 116, 117, 118, 119 and 121; Applied Biosystems). Labeling was
stopped by the addition of 0.1% formic acid. Supernatants were dried down and the eight samples
were mixed to obtain the “8plex-labeled mixture”. The mixture was desalted onto OMIX Pipette tips
C18 until mass spectrometric analysis.
4.9. Reverse Phase-Liquid Chromatography RP-LC-MS/MS and Data Analysis
The desalted 8plex-labeled mixture was dried, resuspended in 10 µL of 0.1% formic acid
and analyzed by Reverse Phase-Liquid Chromatography coupled to tandem Mass Spectrometry
(RP-LC-MS/MS) in an Easy-nLC II system coupled to an ion trap LTQ-Orbitrap-Velos-Pro hybrid
mass spectrometer (Thermo Scientific) as recently described in detail [32]. The instrument method
consisted of a data-dependent top-20 experiment with an Orbitrap MS1 scan at a resolution (m/∆m) of
30,000 followed by either twenty high energy collision dissociation (HCD) MS/MS mass-analyzed in
the Orbitrap at 7500 (∆m/m) resolution. MS2 experiments were performed using HCD to generate
high resolution and high mass accuracy MS2 spectra. The minimum MS signal for triggering
MS/MS was set to 500. The lock mass option was enabled for both MS and MS/MS mode and the
polydimethylcyclosiloxane ions (protonated (Si(CH3)2O))6; m/z 445.120025) were used for internal
recalibration of the mass spectra. Peptides were detected in survey scans from 400 to 1600 amu (1 µscan)
using an isolation width of 2 u (in mass-to-charge ratio units), normalized collision energy of 40%
for HCD fragmentation, and dynamic exclusion applied during 30 seconds periods. Precursors of
unknown or +1 charge state were rejected.
Protein identification and quantification from raw data was carried out using the SEQUEST
algorithm (Proteome Discoverer 1.4, Thermo Scientific) and PEAKS 8 (Bioinformatics Solutions,
Waterloo, ON, Canada). Database search was performed against uniprot-Homo.fasta with the constrains
described in detail [32] and iTRAQ reagent labeling at the N-terminus and lysine residues. Search
against decoy database using false discovery rate (FDR) < 0.01. All proteins were identified with at
least two high confidence peptides.
Cancers 2020, 12, 22 15 of 19
4.10. Immunohistochemistry
Formalin-fixed normal and tumor specimens of the colon were immunostained using the
monoclonal anti-IF1 (1:200) antibody [12]. Sections were counterstained with hematoxylin.
4.11. Cellular Proliferation, Cell Death Assays and Cellular Respiration
Cellular proliferation was determined by protein concentration after 24 h, 48 h, 72 h and 96 h
of culture and by the incorporation of 5-ethynyl-20deoxy-uridine (EdU) into cellular DNA using
the Click-iT EdU Flow Cytometry Assay Kit (Molecular Probes, Thermo Fisher) [11]. For cell death
assays, 50,000 cells/well were seeded and treated with staurosporine (STS) or hydrogen peroxide
(H2O2). Cell death was determined by flow cytometry after staining with Annexin V (ApoScreen
FITC; SouthernBiotech, USA and Canada) [11]. Oxygen consumption rates were determined in an
XF24 Extracellular Flux Analyzer (Agilent Technologies) using 10 mM glucose, 1 mM pyruvate and
2 mM glutamine. Cells were seeded in the microplates, and incubated at 37 ◦C and 5% CO2 for
24 h. The final concentration and order of injected substances was 6 µM oligomycin, 0.75 mM DNP
(2,4-dinitrophenol), 1 µM rotenone and 1 µM antimycin.
4.12. Soft-Agar, Wound Healing, Invasion and Anoikis Assays
For soft-agar assays, 2000 cells were used and layered onto complete growth media plus 0.7% of
agar as recently described in detail [24]. Viable colony numbers were stained and counted using ImageJ
software. For wound healing assays [24], confluent cell monolayers were mechanically disrupted to
produce a uniform scratch and photographed every 30 minutes. Gap distances were analyzed with
Image J software. Corning Biocoat Matrigel Invasion Chambers (8.0 µm pore size) were used to quantify
the cellular invasive capacity. A total of 2 × 104 cells were seeded in 1% FBS and chemoattraction
perform during 72 h in 20% FBS. Anoikis resistance was determined using Cytoselect 96-well Anoikis
Assay (Cell Biolabs, San Diego, CA, USA). 12,000 cells were seeded into each well, and 24 hours later cell
viability and cell death were measured by Calcein Am and EthD-1 fluorometric detection, respectively.
4.13. In Vivo Assays
Mice experiments were carried out in accordance with EU Directive 2010/63/EU for animal
experiments and the methodologies approved by the Ethical Committee of the Universidad Autónoma
de Madrid (CEI-52-961). Approximately, 4 × 106 HCT116-luc shIF1 cells were injected subcutaneously
into the left flank of 6-week-old nude mice (Envigo, Huntingdon, Cambridgeshire, UK). The same
number of HCT116-luc IF1 overexpressing cells was injected into the right flank of the same animals.
Tumor growth was followed every week after implantation of the cells by the intraperitoneal injection
of 150 mg/kg of body weight of D-luciferin (Promega, Madison, WI, USA) utilizing the IVIS Lumina II
equipment (Caliper Life Sciences, Hopkinton, MA, USA). Tumor size was determined using a standard
caliper [53]. Following the ethical criteria established by our Institutional Review Board the animals
were killed when the tumor volume reached 2000 mm3. To study metastasis in vivo, female nude
mice were inoculated with 8 × 106 HCT-luc IF1 overexpressing or HCT-luc IF1 silenced cells (seven
mice per group) through the tail vain. Metastatic disease was monitored by in vivo imaging of the
anesthetized mice after the i.p. administration of luciferin using the IVIS Lumina II imaging system.
Animals were followed during a maximum of 4 weeks and euthanized under CO2 stream followed by
cervical dislocation.
4.14. Flow Cytometry Analyses of Spheroid Invasion
IF1 and shIF1 HCT116 cells were stained with CellTrace™ Violet (CTV) (ThermoFisher, C34557)
in serum-free DMEM media (1:1,000) for 20 minutes at room temperature. CountBright™ Absolute
Counting Beads (Cat. No. C36950, ThermoFisher Scientific) were used to quantify the number of
invading NK cells (CD 45+) by flow cytometry. For each analysis, 10,000 events were recorded.
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4.15. In-Vivo Confocal Microscopy of NK cell Invasion and Cytotoxicity
In-vivo analysis of the interaction between NK cells and colonospheres was performed on Nuclon
Sphera 96F bottom plate (Cat. No. 174927, ThermoFisher Scientific) in RPMI medium supplemented
with IL-2 and IL-15. Pictures were taken in an inverted Axiovert200 (Zeiss, Oberkochen, Germany)
microscope with a scientific complementary metal-oxide semiconductor (sCMOS) monochrome camera
and 10× objective, for 48 h at 37 ◦C and 0.5% CO2. The anti-CD45 APC conjugated antibody (BD
Bioscience) was used at a 1:10 dilution to stain NK cells. Immunofluorescence microscopy of 4%
PFA-fixed colonospheres was used to analyze the infiltration of NK cells. The anti-Phospho-p53 (Ser15)
antibody (Cell Signaling) was used at a 1:100 dilution to assess the rate of cell death in colonospheres.
Nuclei were counterstained with DAPI (diamidino-2-fenilindol) 1:5000. Cellular fluorescence was
analyzed by confocal microscopy in a Nikon A1R + microscope. The area and cell number were
quantified by ImageJ 1.51w software.
4.16. Statistical Analysis
The results shown are the means ± SEM. Statistical analysis were performed by Student’s t-test,
Mann–Whitney U test and/or Kruskal Wallis as appropriate. Tests were calculated using the SPSS 13.0
software package (IBM, Chicago, IL, USA). Survival curves were derived from Kaplan–Meier estimates
and compared by log-rank test. The mean value of IF1 expression in normal samples was used as
cut-off in Kaplan–Meier. The hazard ratio (HR) with 95% confidence interval (CI) was calculated
using univariate and multivariate Cox proportional hazards regression analysis. Statistical tests were
two-tailed at the 5% level of significance.
5. Conclusions
In summary, we demonstrated that the IF1 content in colorectal carcinomas was an independent
predictor of prognosis for CRC patients. In contrast to the pro-oncogenic role of IF1 in other carcinomas,
the overexpression of IF1 in CRC is a biomarker of good prognosis. Molecular and functional analyses
of colon cancer cells with differential expression of IF1 indicate that cells overexpressing IF1 have
lower mitochondrial respiration and a less aggressive phenotype because they are more vulnerable to
death upon cell detachment. In vivo assays confirmed the higher metastatic potential of the cells with
higher respiratory activity as a result of a low mitochondrial content of IF1. Moreover, infiltration and
cytotoxicity of NK cells in tumor spheroids confirmed that carcinomas with high IF1 content were more
vulnerable to immune surveillance. Taken together, these data indicated that IF1 was a biomarker
and prognostic factor of CRC and provided the molecular bases for its tumor suppressor function in
colon cancer.
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